Ted Skolarus to Androstenes
This is a "connection" page, showing publications Ted Skolarus has written about Androstenes.
Connection Strength
1.801
-
Survival by first-line therapy and prognostic group among men with metastatic castration-resistant prostate cancer. Cancer Med. 2024 Jun; 13(12):e7334.
Score: 0.922
-
Early National Dissemination of Abiraterone and Enzalutamide for Advanced Prostate Cancer in Medicare Part D. J Oncol Pract. 2017 08; 13(8):e694-e702.
Score: 0.569
-
Adoption of Abiraterone and Enzalutamide by Urologists. Urology. 2019 09; 131:176-183.
Score: 0.163
-
Mental health care utilization among men with castration-resistant prostate cancer receiving abiraterone or enzalutamide. Cancer Med. 2023 08; 12(15):16490-16501.
Score: 0.054
-
Promotional Payments to Medical Oncologists and Urologists and Prescriptions for Abiraterone and Enzalutamide. Urology. 2022 03; 161:50-58.
Score: 0.048
-
Adherence and out-of-pocket costs among Medicare beneficiaries who are prescribed oral targeted therapies for advanced prostate cancer. Cancer. 2020 12 01; 126(23):5050-5059.
Score: 0.045